Immune effector cell therapies in oncology: A systematic analysis and forecast from ClinicalTrials.gov.

• DOI: 10.1200/jco.2021.39.15_suppl.e14516
• Publication Date: 2021-06-02T14:00:38Z
• Authors: Jose Vicente Fore...; Juan Esteban Garc...; Daniela A. Castro...; Eider Felipe Moreno; Paula Andrea Leng...; Natalie Booth; Januario E. Castro
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e14516 Background: IEC are arguably the most promising therapy in oncology, and FDA approvals for CAR T cells a testament to their real potential. This has led great growth of clinical trials (CT), making evaluation associated data increasingly challenging. To facilitate this process, we performed systematic review ClinicalTrials.gov focused on therapies oncology. We an analysis CT forecast trends 2025. Methods: registries were retrieved from with search query. included registered between 1993-2020, which used IEC-based Statistical using descriptive inferential methods allowed us identify establish forecasts. Results: identified 938 registrations IEC-CTs 51% those active. The common type was (51%), followed by NK (15%), TCR (8%), TIL CIK (3%). 69% aimed at specific target vs. 31% that lack specificity. number annual T-CTs continue increase, 320 during Since 2018, CTs unmodified increased (largely due metastatic melanoma studies). represent 8% all registrations, 2025 anticipate >150 NK-based will be per year, similar 2020. based allogeneic sources 18% expected grow 2.5 fold next 5 years. In solid tumors, Non-CAR studies, while hem-malignancies 76% T. Only one tumor, T-CT, reached phase 2/3, 7 CIK-CTs various organ tumors. Conclusions: exponentially active field research Allogeneic NK-CTs increase rapidly among IEC-CTs. A rising proportion tumors rather than T-cells, more popular treating hem-malignancies. is direct reflection challenges infiltration persistence Our analyses indicate double cellular options demand organized response, including adequate logistical planning policy implementation response landscape changes oncology upcoming years.[Table: see text]